Page 987 - Williams Hematology ( PDFDrive )

962 Part VII: Neutrophils, Eosinophils, Basophils, and Mast Cells Chapter 62: Eosinophils and Related Disorders 963

93. Lee JJ, Jacobsen EA, McGarry MP, et al: Eosinophils in health and disease: The LIAR 129. Gouon-Evans V, Rothenberg ME, Pollard JW: Postnatal mammary gland development
hypothesis. Clin Exp Allergy 40:563–575, 2010. requires macrophages and eosinophils. Development 127:2269–2282, 2000.
94. Akuthota P, Wang HB, Spencer LA, et al: Immunoregulatory roles of eosinophils: A 130. Klion AD, Nutman TB: The role of eosinophils in host defense against helminth para-
new look at a familiar cell. Clin Exp Allergy 38:1254–1263, 2008. sites. J Allergy Clin Immunol 113:30–37, 2004.
95. Heredia JE, Mukundan L, Chen FM, et al: Type 2 innate signals stimulate fibro/ 131. Percopo CM, Dyer KD, Ochkur SI, et al: Activated mouse eosinophils protect against
adipogenic progenitors to facilitate muscle regeneration. Cell 153:376–388, 2013. lethal respiratory virus infection. Blood 123:743–752, 2014.
96. Goh YP, Henderson NC, Heredia JE, et al: Eosinophils secrete IL-4 to facilitate liver 132. Lilly LM, Scopel M, Nelson MP, et al: Eosinophil deficiency compromises lung defense
regeneration. Proc Natl Acad Sci U S A 110:9914–9919, 2013. against Aspergillus fumigatus. Infect Immun 82:1315–1325, 2014.
97. Wu D, Molofsky AB, Liang HE, et al: Eosinophils sustain adipose alternatively activated 133. Gonem S, Raj V, Wardlaw AJ, et al: Phenotyping airways disease: An A to E approach.
macrophages associated with glucose homeostasis. Science 332:243–247, 2011. Clin Exp Allergy 42:1664–1683, 2012.
98. Lee M, Odegaard JI, Mukundan L, et al: Activated type 2 innate lymphoid cells regulate 134. Haldar P, Pavord ID, Shaw DE, et al: Cluster analysis and clinical asthma phenotypes.
beige fat biogenesis. Cell 160:74–87, 2015. Am J Respir Crit Care Med 178:218–224, 2008.
99. Qiu Y, Nguyen KD, Odegaard JI, et al: Eosinophils and type 2 cytokine signaling in macro- 135. Henderson WR Jr, Chi EY, Albert RK, et al: Blockade of CD49d (alpha4 integrin)
phages orchestrate development of functional beige fat. Cell 157:1292–1308, 2014. on intrapulmonary but not circulating leukocytes inhibits airway inflammation and
100. Chu VT, Frohlich A, Steinhauser G, et al: Eosinophils are required for the maintenance hyperresponsiveness in a mouse model of asthma. J Clin Invest 100:3083–3092, 1997.
of plasma cells in the bone marrow. Nat Immunol 12:151–159, 2011. 136. Nair P, Pizzichini MM, Kjarsgaard M, et al: Mepolizumab for prednisone-dependent
101. Chu VT, Beller A, Rausch S, et al: Eosinophils promote generation and maintenance of asthma with sputum eosinophilia. N Engl J Med 360:985–993, 2009.
immunoglobulin-A-expressing plasma cells and contribute to gut immune homeosta- 137. Haldar P, Brightling CE, Hargadon B, et al: Mepolizumab and exacerbations of refrac-
sis. Immunity 40:582–593, 2014. tory eosinophilic asthma. N Engl J Med 360:973–984, 2009.
102. Wong TW, Doyle AD, Lee JJ, et al: Eosinophils regulate peripheral B cell numbers in 138. Pavord ID, Korn S, Howarth P, et al: Mepolizumab for severe eosinophilic asthma
both mice and humans. J Immunol 192:3548–3558, 2014. (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 380:651–659,
103. Bandeira-Melo C, Weller PF: Eosinophils and cysteinyl leukotrienes. Prostaglandins 2012.
Leukot Essent Fatty Acids 69:135–143, 2003. 139. Ortega HG, Liu MC, Pavord ID, et al: Mepolizumab treatment in patients with severe
104. Luna-Gomes T, Magalhaes KG, Mesquita-Santos FP, et al: Eosinophils as a novel eosinophilic asthma. N Engl J Med 371:1198–1207, 2014.
cell source of prostaglandin D2: Autocrine role in allergic inflammation. J Immunol 140. Johansson MW, Gunderson KA, Kelly EA, et al: Anti-IL-5 attenuates activation and
187:6518–6526, 2011. surface density of beta(2)-integrins on circulating eosinophils after segmental antigen
105. Bozza PT, Yu W, Penrose JF, et al: Eosinophil lipid bodies: Specific, inducible intracellu- challenge. Clin Exp Allergy 43:292–303, 2013.
lar sites for enhanced eicosanoid formation. J Exp Med 186:909–920, 1997. 141. Leiferman KM, Gleich GJ: Hypereosinophilic syndrome: Case presentation and update.
106. Flood-Page P, Menzies-Gow A, Phipps S, et al: Anti-IL-5 treatment reduces deposi- J Allergy Clin Immunol 113:50–58, 2004.
tion of ECM proteins in the bronchial subepithelial basement membrane of mild atopic 142. Simon D, Braathen LR, Simon HU: Eosinophils and atopic dermatitis. Allergy 59:
asthmatics. J Clin Invest 112:1029–1036, 2003. 561–570, 2004.
107. Phipps S, Ying S, Wangoo A, et al: The relationship between allergen-induced tissue 143. Leiferman KM, Gleich GJ, Peters MS: Dermatologic manifestations of the hypereosin-
eosinophilia and markers of repair and remodeling in human atopic skin. J Immunol ophilic syndromes. Immunol Allergy Clin North Am 27:415–441, 2007.
169:4604–4612, 2002. 144. Rothenberg ME: Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immu-
108. Brightling CE, Bradding P, Symon FA, et al: Mast-cell infiltration of airway smooth nol 113:11–28; quiz 29, 2004.
muscle in asthma. N Engl J Med 346:1699–1705, 2002. 145. Abonia JP, Rothenberg ME: Eosinophilic esophagitis: Rapidly advancing insights. Annu
109. Acharya KR, Ackerman SJ: Eosinophil granule proteins: Form and function. J Biol Rev Med 63:421–434, 2012.
Chem 289:17406–17415, 2014. 146. Sher A, Coffman RL, Hieny S, et al: Ablation of eosinophil and IgE responses with
110. Butterworth AE, Sturrock RF, Houba V, et al: Eosinophils as mediators of antibody-de- anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni
pendent damage to schistosomula. Nature 256:727–729, 1975. in the mouse. J Immunol 145:3911–3916, 1990.
111. Gleich GJ: Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 147. Herbert DR, Lee JJ, Lee NA, et al: Role of IL-5 in innate and adaptive immunity to larval
105:651–663, 2000. Strongyloides stercoralis in mice. J Immunol 165:4544–4551, 2000.
112. Ackerman SJ, Liu L, Kwatia MA, et al: Charcot-Leyden crystal protein (galectin-10) is 148. Huang L, Gebreselassie NG, Gagliardo LF, et al: Eosinophil-derived IL-10 supports
not a dual function galectin with lysophospholipase activity but binds a lysophospholi- chronic nematode infection. J Immunol 193:4178–4187, 2014.
pase inhibitor in a novel structural fashion. J Biol Chem 277:14859–14868, 2002. 149. Huang L, Gebreselassie NG, Gagliardo LF, et al: Eosinophils mediate protective immu-
113. Persson C, Uller L: Theirs but to die and do: Primary lysis of eosinophils and free eos- nity against secondary nematode infection. J Immunol 194:283–290, 2015.
inophil granules in asthma. Am J Respir Crit Care Med 189:628–633, 2014. 150. Neill DR, Wong SH, Bellosi A, et al: Nuocytes represent a new innate effector leukocyte
114. Ueki S, Melo RC, Ghiran I, et al: Eosinophil extracellular DNA trap cell death medi- that mediates type-2 immunity. Nature 464:1367–1370, 2010.
ates lytic release of free secretion-competent eosinophil granules in humans. Blood 151. Patnode ML, Bando JK, Krummel MF, et al: Leukotriene B4 amplifies eosinophil accu-
121:2074–2083, 2013. mulation in response to nematodes. J Exp Med 211:1281–1288, 2014.
115. Simon D, Hoesli S, Roth N, et al: Eosinophil extracellular DNA traps in skin diseases. J 152. Hardy WR, Anderson RE: The hypereosinophilic syndromes. Ann Intern Med 68:
Allergy Clin Immunol 127:194–199, 2011. 1220–1229, 1968.
116. Pazdrak K, Young TW, Straub C, et al: Priming of eosinophils by GM-CSF is mediated 153. Chusid MJ, Dale DC, West BC, et al: The hypereosinophilic syndrome: Analysis of four-
by protein kinase CbetaII-phosphorylated L-plastin. J Immunol 186:6485–6496, 2011. teen cases with review of the literature. Medicine (Baltimore) 54:1–27, 1975.
117. Seminario MC, Saini SS, MacGlashan DW Jr, et al: Intracellular expression and release 154. Ogbogu PU, Bochner BS, Butterfield JH, et al: Hypereosinophilic syndrome: A multi-
of Fc epsilon RI alpha by human eosinophils. J Immunol 162:6893–6900, 1999. center, retrospective analysis of clinical characteristics and response to therapy. J Allergy
118. Kaneko M, Horie S, Kato M, et al: A crucial role for beta 2 integrin in the activation of Clin Immunol 124:1319–1325.e3, 2009.
eosinophils stimulated by IgG. J Immunol 155:2631–2641, 1995. 155. Valent P, Klion AD, Horny HP, et al: Contemporary consensus proposal on criteria and
119. Kovacs I, Horvath M, Kovacs T, et al: Comparison of proton channel, phagocyte oxi- classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol
dase, and respiratory burst levels between human eosinophil and neutrophil granulo- 130:607–612.e9, 2012.
cytes. Free Radic Res 48:1190–1199, 2014. 156. Simon HU, Rothenberg ME, Bochner BS, et al: Refining the definition of hypereosino-
120. Odemuyiwa SO, Ilarraza R, Davoine F, et al: Cyclin-dependent kinase 5 regulates philic syndrome. J Allergy Clin Immunol 126:45–49, 2010.
degranulation in human eosinophils. Immunology. 144(4):641–648, 2015. 157. Gotlib J: World Health Organization-defined eosinophilic disorders: 2014 update on
121. Kimura I, Moritani Y, Tanizaki Y: Basophils in bronchial asthma with reference to diagnosis, risk stratification, and management. Am J Hematol 89:325–337, 2014.
reagin-type allergy. Clin Allergy 3:195–202, 1973. 158. Sheikh J, Weller PF: Advances in diagnosis and treatment of eosinophilia. Curr Opin
122. Krause JR, Boggs DR: Search for eosinopenia in hospitalized patients with normal Hematol 16:3–8, 2009.
blood leukocyte concentration. Am J Hematol 24:55–63, 1987. 159. Cools J, DeAngelo DJ, Gotlib J, et al: A tyrosine kinase created by fusion of the PDG-
123. Gudbjartsson DF, Bjornsdottir US, Halapi E, et al: Sequence variants affecting eosino- FRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosino-
phil numbers associate with asthma and myocardial infarction. Nat Genet 41:342–347, philic syndrome. N Engl J Med 348:1201–1214, 2003.
2009. 160. Griffin JH, Leung J, Bruner RJ, et al: Discovery of a fusion kinase in EOL-1
124. Juhlin L, Michaelsson G: A new syndrome characterised by absence of eosinophils and cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 100:
basophils. Lancet 1:1233–1235, 1977. 7830–7835, 2003.
125. Roufosse F, Weller PF: Practical approach to the patient with hypereosinophilia. J 161. Fletcher S, Bain B: Diagnosis and treatment of hypereosinophilic syndromes. Curr Opin
Allergy Clin Immunol 126:39–44, 2010. Hematol 14:37–42, 2007.
126. Wechsler ME: Pulmonary eosinophilic syndromes. Immunol Allergy Clin North Am 162. Musto P, Perla G, Minervini MM, et al: Imatinib-mesylate for all patients with hypereo-
27:477–492, 2007. sinophilic syndrome? Leuk Res 28:773–774, 2004.
127. Bochner BS: Verdict in the case of therapies versus eosinophils: The jury is still out. J 163. Helbig G, Stella-Holowiecka B, Majewski M, et al: Interferon alpha induces a good
Allergy Clin Immunol 113:3–9; quiz 10, 2004. molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the
128. Todd R, Donoff BR, Chiang T, et al: The eosinophil as a cellular source of transforming JAK2V617F point mutation. Haematologica 92:e118–e119, 2007.
growth factor alpha in healing cutaneous wounds. Am J Pathol 138:1307–1313, 1991. 164. Noel P: Eosinophilic myeloid disorders. Semin Hematol 49:120–127, 2012.

Kaushansky_chapter 62_p0947-0964.indd 962 9/21/15 10:56 AM